Shares of Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) have received a consensus recommendation of “Buy” from the fifteen ...

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00.UBS Group currently has a buy ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

Gil Blum, an analyst from Needham, maintained the Buy rating on Taysha Gene Therapies (TSHA – Research Report). The associated price target ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.57 billion, has been making waves in the cell therapy space with its innovative approach to treating multiple myeloma and ...

Generation Bio (GBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech. Legend has downplayed the ...

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.